BTAI
BioXcel Therapeutics, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C
Company Profile
CEO
Vimal D. Mehta
IPO Date
2018-03-08
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
BioXcel Therapeutics, Inc.
CEO
Vimal D. Mehta
IPO Date
2018-03-08
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 6,845 |
| $1.08 |
| 22 May 2026 | Yocca Frank | Chief Scientific Officer | M-Exempt | Disposed | 17,500 | $0.00 |
| 22 May 2026 | Rodriguez Javier | See Remarks | M-Exempt | Acquired | 17,500 | $0.00 |
| 22 May 2026 | Rodriguez Javier | See Remarks | S-Sale | Disposed | 6,560 | $1.08 |
| 22 May 2026 | Rodriguez Javier | See Remarks | M-Exempt | Disposed | 17,500 | $0.00 |
| 22 May 2026 | Steinhart Richard I | Chief Financial Officer | M-Exempt | Acquired | 17,500 | $0.00 |
| 22 May 2026 | Steinhart Richard I | Chief Financial Officer | S-Sale | Disposed | 6,845 | $1.08 |
| 22 May 2026 | Steinhart Richard I | Chief Financial Officer | M-Exempt | Disposed | 17,500 | $0.00 |
| 22 May 2026 | Mehta Vimal | director, officer: CEO and President | M-Exempt | Acquired | 49,758 | $0.00 |